Mana Capital Acquisition (MAAQ) Competitors $4.23 -0.30 (-6.62%) As of 06/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MAAQ vs. BDTX, KYTX, IKT, EPRX, SPRO, KRRO, NKTX, FTLF, GLSI, and TARAShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Black Diamond Therapeutics (BDTX), Kyverna Therapeutics (KYTX), Inhibikase Therapeutics (IKT), Eupraxia Pharmaceuticals (EPRX), Spero Therapeutics (SPRO), Korro Bio (KRRO), Nkarta (NKTX), FitLife Brands (FTLF), Greenwich LifeSciences (GLSI), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Its Competitors Black Diamond Therapeutics Kyverna Therapeutics Inhibikase Therapeutics Eupraxia Pharmaceuticals Spero Therapeutics Korro Bio Nkarta FitLife Brands Greenwich LifeSciences Protara Therapeutics Black Diamond Therapeutics (NASDAQ:BDTX) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations. Is BDTX or MAAQ more profitable? Mana Capital Acquisition's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% Mana Capital Acquisition N/A N/A N/A Does the media favor BDTX or MAAQ? In the previous week, Black Diamond Therapeutics had 4 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 4 mentions for Black Diamond Therapeutics and 0 mentions for Mana Capital Acquisition. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Mana Capital Acquisition's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Black Diamond Therapeutics Positive Mana Capital Acquisition Neutral Which has higher earnings and valuation, BDTX or MAAQ? Mana Capital Acquisition has lower revenue, but higher earnings than Black Diamond Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond Therapeutics$70M1.98-$82.44M$0.0640.67Mana Capital AcquisitionN/AN/AN/AN/AN/A Does the MarketBeat Community believe in BDTX or MAAQ? Black Diamond Therapeutics received 55 more outperform votes than Mana Capital Acquisition when rated by MarketBeat users. However, 100.00% of users gave Mana Capital Acquisition an outperform vote while only 70.89% of users gave Black Diamond Therapeutics an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5670.89% Underperform Votes2329.11% Mana Capital AcquisitionOutperform Votes1100.00% Underperform VotesNo Votes Do analysts recommend BDTX or MAAQ? Black Diamond Therapeutics presently has a consensus target price of $14.60, suggesting a potential upside of 498.36%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in BDTX or MAAQ? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 6.0% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryBlack Diamond Therapeutics beats Mana Capital Acquisition on 9 of the 12 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$34.37M$34.37M$2.04B$8.62BDividend YieldN/AN/A2.61%4.18%P/E RatioN/AN/A22.6420.00Price / SalesN/AN/A56.18158.30Price / CashN/AN/A51.7234.64Price / BookN/AN/A2.094.70Net IncomeN/AN/A-$292.00M$248.14M7 Day Performance-15.23%-15.23%1.41%2.48%1 Month Performance2,185.25%2,185.25%12.84%6.15%1 Year Performance605.71%605.71%17.89%13.59% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$4.23-6.6%N/A+716.2%$34.37MN/A0.001BDTXBlack Diamond Therapeutics3.4727 of 5 stars$2.58+3.6%$14.60+465.9%-61.1%$146.71M$70M-1.9490Positive NewsGap UpKYTXKyverna Therapeutics2.2135 of 5 stars$3.39+15.3%$18.50+445.7%-74.7%$146.51M$7.03M-1.0096Gap DownIKTInhibikase Therapeutics1.5006 of 5 stars$1.96flat$6.50+231.6%+22.9%$145.71M$260K-0.736Positive NewsEPRXEupraxia Pharmaceuticals2.2979 of 5 stars$3.94-0.1%$10.50+166.8%+38.9%$141.07MN/A-5.4729SPROSpero Therapeutics3.883 of 5 stars$2.50-2.3%$5.00+100.0%+88.6%$139.78M$28.30M35.72150Positive NewsShort Interest ↑High Trading VolumeKRROKorro Bio3.5686 of 5 stars$14.59+18.1%$102.43+602.0%-64.8%$137.02M$4.82M-1.5570Positive NewsAnalyst RevisionHigh Trading VolumeNKTXNkarta3.6632 of 5 stars$1.90+3.8%$14.67+671.9%-69.2%$134.82MN/A-1.01140Positive NewsAnalyst ForecastFTLFFitLife Brands4.2061 of 5 stars$14.31-1.0%$20.50+43.3%-5.9%$134.39M$63.86M16.9320Positive NewsShort Interest ↑GLSIGreenwich LifeSciences2.2811 of 5 stars$9.66+2.4%$39.00+303.7%-32.1%$129.14MN/A-12.073Positive NewsTARAProtara Therapeutics2.4763 of 5 stars$3.34+7.1%$20.50+513.8%+20.1%$128.86MN/A-1.1830Positive NewsAnalyst RevisionGap Up Related Companies and Tools Related Companies BDTX Alternatives KYTX Alternatives IKT Alternatives EPRX Alternatives SPRO Alternatives KRRO Alternatives NKTX Alternatives FTLF Alternatives GLSI Alternatives TARA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MAAQ Stock Free MAAQ Stock Alerts